Devita, Hellman, and Rosenberg's Cancer

LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14

Index 607

risk factors of, 231, 238

and smokeless tobacco, 34, 44

tylosis and, 231, 238

Esophagitis, causative agents in, 547

Esophagogastroduodenoscopy, 262

Estrogen receptor (ER), 331, 341

Etoposide (EP), 298, 302

in NSCLC treatment, 213

in SCLC treatment, 207, 211

European Group for Blood and

Marrow Transplantation, 473

European Organization for

Research and Treatment of

Cancer (EORTC), 92

Everolimus, 127, 132

side effects of, 127, 132

Ewing’s sarcoma, 365, 370, 395,

404, 405, 412

cytogenetic abnormalities in, 394,

404

prognostic factors in, 400, 410

recurrence rates in, decreased,

401, 410

site of metastasis in, 400, 410

Excisional biopsy, 80, 83, 379

Exercise, for cancer patients, 573,

577

Expanded access protocols, 584,

587

Extragonadal germ cell tumor, 476,

479–480

Extremity soft tissue sarcomas, 374

Ezrin, circulating tumor cells and,

23, 31

Familial adenomatous polyposis

(FAP), 36, 46, 137, 140, 268,

274

causes of, 46

features of, 36, 46

IRA and, 137, 140

Familial malignant melanoma

syndrome, 18, 27

causes of, 27

Fancgenes, 12

Fanconi anemia, 412, 462

causes of, 12

defects in, 12

repair pathway, ATR/CHK1

signaling in, 12

SCCHN and, 195, 199

FAP.SeeFamilial adenomatous

polyposis (FAP)

Fas, for death receptor pathway,

19, 27

FDA.SeeFood and Drug

Administration (FDA)

FDG.SeeFluorodeoxyglucose

(FDG)

FDG-PET.SeeFluorodeoxyglucose

positron emission tomography

(FDG-PET)

Fecal occult blood testing, in

colorectal cancer, 142, 146

Femoral metastases, indication for

operative management of,

510, 513

Fever, IDSA guidelines on, 540, 545

Fibrolamellar HCC, 255, 259

Fibrous tumors of the pleura (FTP),

484, 485

benign, 485

solitary, 485

Field edge, 86.See alsoLinear

accelerator (LINAC)

FIGO.SeeInternational Federation

of Obstetrician &

Gynecologist (FIGO)

Fine-needle aspiration (FNA), 80,

83, 196

FISH.SeeFluorescence in situ

hybridization (FISH)

Flavopiridol, 99, 103

Flaxseed, 596

FLT3, in leukemias, 438, 443–444

Fludarabine, 124, 130, 455–456

Fluorescence in situ hybridization

(FISH), 437, 443, 450, 454

Fluorodeoxyglucose (FDG), 165,

176, 217, 416

Fluorodeoxyglucose (FDG) PET-CT

imaging, 379

Fluorodeoxyglucose positron

emission tomography

(FDG-PET), 233, 240

extranodal marginal zone

lymphoma and, 416

in lymphoma staging, 416

Fluoropyrimidines, 95, 100

Fluoroquinolones, 544, 549

5-fluorouracil, 32, 87, 92, 161, 170

chemotherapy, 3

microsatellite instability and, 4, 11

FNA.SeeFine-needle aspiration

(FNA)

Focal and segmental

glomerulosclerosis, 519, 523

FOLFIRI chemotherapy, 124, 130

FOLFIRINOX in, pancreatic cancer

treatment, 245, 250–251

Folic acid and lymphoblastic

leukemia, 95, 100

Follicle stimulating hormone (FSH),

221

Follicular lymphoma, 416, 430

ibritumomab and, 128, 132

Food and Drug Administration

(FDA), 316, 324

Food frequency questionnaire, 61,

67

Foster-Kennedy syndrome, 506

Fractionated radiotherapy, 86

FSH.SeeFollicle stimulating

hormone (FSH)

FTP.SeeFibrous tumors of the

pleura (FTP)

Fumarate hydratase gene

hereditary leiomyomatosis and,

280, 289

renal cancer and, 280, 289

5-FU, role of, 123, 129

Gabapentin, in neuropathic pain,

561, 567

Gail model, 333, 342

Gall bladder cancer

adjuvant therapy for, 255, 259

T2 NX stage of, 254, 258

Gallium nitrate, for reduction in

calcium level, 507

Gallium scan, 416, 430

Gastric cancer, 519, 523

adjuvant radiation therapy of,

236, 241–242

chemotherapy in, 236, 242

EBV and, 52

E-cadherin and, 232, 233,

238–239, 239

microsatellite instability in, 233,

237, 239, 243

mitomycin C in, 242

prophylactic gastrectomy in, 237,

243

p53 tumor suppressor gene and,

233, 239

Gastric outlet obstruction,

palliative surgery for, 77, 81

Gastroesophageal (GE)

cancers treatment, trastuzimab in,

232, 238

reflux

Barrett’s esophagus

development and, 238

esophageal cancer risk and, 142,

145

Gastroesophageal junction (GE

junction), 235

Gastrointestinal (GI), 98, 102

Gastrointestinal stromal tumor

(GIST), 261, 265, 367, 371

Carney triad and, 263, 267

familial paraganglioma and, 263,

267

imatinib in, 261, 265–266

neurofibromatosis and, 263,

267

sunitinib therapy, 262, 266